Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
This study is currently recruiting participants.
Verified January 2013 by Stanford University
Information provided by (Responsible Party):
First received: September 6, 2006
Last updated: January 18, 2013
Last verified: January 2013
The objective of the study is to identify novel blood markers for the diagnosis of liver cancer. We will collect serum samples from consented patients and measure the levels of potential protein markers in their serum.
||Observational Model: Cohort
Time Perspective: Prospective
||Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Biospecimen Retention: Samples With DNA
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2014 (Final data collection date for primary outcome measure)
Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and sensitivity. The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with AFP. The aim of this study is to identify new blood markers of liver cancer that can be used to increase the rate of accurate diagnosis of this malignancy.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients diagnosed with liver cancer
Inclusion Criteria:Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Exclusion Criteria:Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00373347
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
|Contact: Mei-Sze Chua 650-724-3525 email@example.com |
|Contact: Cancer Clinical Trials Office (650) 498-7061 |
|Principal Investigator: Samuel So |
No publications provided
History of Changes
|Other Study ID Numbers:
||HEP0006, 95521, HEP0006, 10767
|Study First Received:
||September 6, 2006
||January 18, 2013
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2013
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases